Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (4290)	3/10/2003 5:48:50 PM
From: Hank	Read Replies (1) \| Respond to of 5582

Blah Blah Blah Yackity Yack Yack Yack Danny, you're so full of sht your eyes are brown. If the testimonials are published, then they aren't "countless" are they? And I don't want to hear anymore bullsht about that peer reviewed journal.. It's a joke, as are the federal regulations regarding homeopathic rememdies. But don't worry. The hubub over ephedrine and unic acid may change all that.

To: DanZ who wrote (4290)	3/28/2003 6:19:06 PM
From: StockDung	Respond to of 5582

MTXX filed their 10K, in the income statement it show a Benfit! for taxes ie not a charge of 3,709,947 against operating income of $1,046,708. Because it is a "benefit" you add them to get to a net income of 4,756,655. By doing this MTXX showed earnings of 50 cents. Had they not had any 'benifit" they would have had 11 cents. had they paid 38% tax rate, it would have been 7 cents.

To: DanZ who wrote (4290)	4/16/2003 2:01:05 PM
From: StockDung	Read Replies (1) \| Respond to of 5582

Zila Rejects Matrixx Claims 2003-04-16 08:05 (New York) News Editors/Business Editors/Health/Medical Writers PHOENIX--(BUSINESS WIRE)--April 16, 2003--Zila, Inc. (Nasdaq:ZILA)--On April 4, 2003 Matrixx Initiatives, Inc. ("Matrixx") commenced arbitration proceedings against the Company's Zila Swab Technologies, Inc. subsidiary ("ZST") and filed a claim against the Company and ZST in the Superior Court of Arizona seeking a temporary restraining order ("TRO"). Under its arbitration claim, which seeks monetary damages, Matrixx alleges that ZST breached certain of its obligations by failing to produce requested levels of swabs for Matrixx under a swab manufacturing contract and by raising its prices. In the TRO action Matrixx seeks to require ZST to produce at requested levels and at the former prices. Zila and ZST believe the claims are wholly without merit and intend to vigorously defend these actions. It is Zila's policy to aggressively pursue all appropriate courses of action to protect the interest of Zila and its shareholders. About Zila Zila, Inc., headquartered in Phoenix, is an international provider of healthcare and biotechnology products for dental/medical professionals and consumers. Zila has three business units: Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila(R) Tolonium Chloride and OraTest(R) technologies. Zila Pharmaceuticals, "The Oral Soft Tissue Experts" marketing ViziLite(TM) oral examination kits, Zilactin(R) OTC oral care products, and Peridex(R) prescription periodontal rinse. Zila Nutraceuticals, manufacturer and marketer of Ester-C(R), a branded, superior efficacy nutrition product. For more information about Zila, visit www.zila.com. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs, including litigation. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K and 10-K/A for its fiscal year ended July 31, 2002, and its Form 10-Q for the quarter ended January 31, 2003, filed with the Securities and Exchange Commission. --30--MCC/sf* CONTACT: ZILA, Inc., Phoenix Doug Burkett, 602/266-6700 KEYWORD: ARIZONA INDUSTRY KEYWORD: LEGAL/LAW MANUFACTURING PHARMACEUTICAL BIOTECHNOLOGY CLASS ACTION LAWSUITS PRODUCT SOURCE: ZILA, INC. Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com -0- Apr/16/2003 12:05 GMT

To: DanZ who wrote (4290)	4/24/2003 9:42:08 AM
From: StockDung	Read Replies (1) \| Respond to of 5582

"Court Rules in Zila's Favor; Denies Matrixx Request for Temporary Order 2003-04-23 08:05 (New York) Business Editors/Health/Medical Writers PHOENIX--(BUSINESS WIRE)--April 23, 2003--Zila, Inc. (Nasdaq:ZILA) announced that an Arizona Superior Court Judge has denied the request of Matrixx Initiatives, Inc. (Matrixx) for a temporary restraining order (TRO) against Zila Swab Technologies, Inc. (ZST), a subsidiary of Zila, Inc. The TRO would have prohibited ZST from raising prices under its contract with Matrixx. Earlier this year ZST increased its prices to Matrixx under the contract. On April 4, 2003, Matrixx commenced arbitration proceedings against ZST and filed a claim against Zila and ZST in the Arizona Superior Court seeking the TRO and damages. In order to have a TRO issued, the party seeking it must, among other factors, demonstrate a strong likelihood of succeeding on the merits of the case. In this regard, the Court stated, "On the record before it, this Court cannot determine that Matrixx will succeed on the claims relating to the contract interpretation." Zila and ZST believe the Matrixx claims are wholly without merit. Zila has filed a motion to dismiss the remainder of the Superior Court action. It will continue to pursue aggressively all appropriate courses of action to protect the interests of Zila and its shareholders. About Zila Zila, Inc., headquartered in Phoenix, is an international provider of healthcare and biotechnology products for dental/medical professionals and consumers. Zila has three business units: -- Zila Biotechnology, a research, development and licensing business specializing in pre-cancer/cancer detection through its patented Zila(R) Tolonium Chloride and OraTest(R) technologies. -- Zila Pharmaceuticals, "The Oral Soft Tissue Experts" marketing ViziLite(TM) oral examination kits, Zilactin(R) OTC oral care products, and Peridex(R) prescription periodontal rinse. -- Zila Nutraceuticals, manufacturer and marketer of Ester-C(R), a branded, superior efficacy nutrition product. For more information about Zila, visit www.zila.com. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs, including litigation. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K and 10-K/A for its fiscal year ended July 31, 2002, and its Form 10-Q for the quarter ended January 31, 2003, filed with the Securities and Exchange Commission. --30--VS/cg* CONTACT: Zila, Inc., Phoenix Doug Burkett, Ph.D., 602/266-6700 KEYWORD: ARIZONA INDUSTRY KEYWORD: LEGAL/LAW MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Zila, Inc. Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com -0- Apr/23/2003 12:05 GMT